Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonidegib for biomarker-selected advanced solid cancers
ACTRN12623001216606Phase 2Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Dec 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonidegib, sponsored by Northern Sydney Local Health District. Primary endpoint: Activity of mutation and/or elevated Hedgehog expression-directed sonidegib. Started Dec 2023; status: recruiting.
02
Drugs
sonidegib
Beyond the preview
Go deeper on ACTRN12623001216606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001216606.